1. Home
  2. SPRO vs BRFH Comparison

SPRO vs BRFH Comparison

Compare SPRO & BRFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • BRFH
  • Stock Information
  • Founded
  • SPRO 2013
  • BRFH 2005
  • Country
  • SPRO United States
  • BRFH United States
  • Employees
  • SPRO N/A
  • BRFH N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • BRFH Packaged Foods
  • Sector
  • SPRO Health Care
  • BRFH Consumer Staples
  • Exchange
  • SPRO Nasdaq
  • BRFH Nasdaq
  • Market Cap
  • SPRO 74.0M
  • BRFH 64.3M
  • IPO Year
  • SPRO 2017
  • BRFH N/A
  • Fundamental
  • Price
  • SPRO $1.31
  • BRFH $3.39
  • Analyst Decision
  • SPRO Strong Buy
  • BRFH Strong Buy
  • Analyst Count
  • SPRO 3
  • BRFH 1
  • Target Price
  • SPRO $7.00
  • BRFH $4.50
  • AVG Volume (30 Days)
  • SPRO 124.6K
  • BRFH 13.2K
  • Earning Date
  • SPRO 08-05-2024
  • BRFH 10-24-2024
  • Dividend Yield
  • SPRO N/A
  • BRFH N/A
  • EPS Growth
  • SPRO N/A
  • BRFH N/A
  • EPS
  • SPRO 0.33
  • BRFH N/A
  • Revenue
  • SPRO $118,459,000.00
  • BRFH $8,818,000.00
  • Revenue This Year
  • SPRO N/A
  • BRFH $54.17
  • Revenue Next Year
  • SPRO N/A
  • BRFH $42.41
  • P/E Ratio
  • SPRO $4.12
  • BRFH N/A
  • Revenue Growth
  • SPRO 118.43
  • BRFH 18.54
  • 52 Week Low
  • SPRO $0.99
  • BRFH $1.00
  • 52 Week High
  • SPRO $1.89
  • BRFH $4.61
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 51.95
  • BRFH 44.77
  • Support Level
  • SPRO $1.32
  • BRFH $3.30
  • Resistance Level
  • SPRO $1.37
  • BRFH $3.58
  • Average True Range (ATR)
  • SPRO 0.05
  • BRFH 0.16
  • MACD
  • SPRO 0.00
  • BRFH -0.01
  • Stochastic Oscillator
  • SPRO 41.18
  • BRFH 2.06

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About BRFH Barfresh Food Group Inc.

Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.

Share on Social Networks: